Clinical efficacy of combined topical 0.05% cyclosporine A and 0.1% sodium hyaluronate in the dry eyes with meibomian gland dysfunction

AIM: To investigate the efficacy of combined topical 0.05% cyclosporine A (CsA; Restasis®, Allergan pharmaceuticals, USA) and 0.1% sodium hyaluronate treatment in dry eyes with meibomian gland dysfunction (MGD). METHODS: In a retrospective analysis, 53 patients (106 eyes) with MGD were enrolled and...

Full description

Bibliographic Details
Main Authors: Ho-Yun Kim, Ji-Eun Lee, Ha-Na Oh, Ju-Whan Song, Sang-Youp Han, Jong-Soo Lee
Format: Article
Language:English
Published: Press of International Journal of Ophthalmology (IJO PRESS) 2018-04-01
Series:International Journal of Ophthalmology
Subjects:
600
Online Access:http://www.ijo.cn/en_publish/2018/4/20180409.pdf
id doaj-9ac8b8eb245d4bc8b3cf84493f11f0d9
record_format Article
spelling doaj-9ac8b8eb245d4bc8b3cf84493f11f0d92020-11-24T22:39:21ZengPress of International Journal of Ophthalmology (IJO PRESS)International Journal of Ophthalmology2222-39592227-48982018-04-0111459360010.18240/ijo.2018.04.09Clinical efficacy of combined topical 0.05% cyclosporine A and 0.1% sodium hyaluronate in the dry eyes with meibomian gland dysfunctionHo-Yun Kim0Ji-Eun Lee1Ha-Na Oh2Ju-Whan Song3Sang-Youp Han4Jong-Soo Lee5Department of Ophthalmology, Maryknoll Medical Center, Busan 48972, South KoreaDepartment of Ophthalmology, Pusan National University Yangsan Hospital, Yangsan 50612, South KoreaDepartment of Ophthalmology, Inje University Baek Hospital, Busan 47392, South KoreaDepartment of Ophthalmology, Kosin University hospital, Busan 49267, South KoreaSungmo Eye Clinic, Busan 48064, South KoreaDepartment of Ophthalmology, Pusan National University Hospital, Busan 49241, South Korea; Medical Research Institute, Pusan National University Hospital, Busan 49241, South KoreaAIM: To investigate the efficacy of combined topical 0.05% cyclosporine A (CsA; Restasis®, Allergan pharmaceuticals, USA) and 0.1% sodium hyaluronate treatment in dry eyes with meibomian gland dysfunction (MGD). METHODS: In a retrospective analysis, 53 patients (106 eyes) with MGD were enrolled and performed lid warm massage for 10min daily and be instilled preservative free sodium hyaluronate 0.1% eye drops 4 times daily. Patients were divided into subjects treated with topical 0.05% CsA and preservative free sodium hyaluronate vehicle (experimental group, n=74 eyes) and subjects treated with the preservative free sodium hyaluronate vehicle (control group, n=32 eyes). They were evaluated at baseline and 1, 2, and 3mo for subjective symptoms and objective signs including tear film break-up time (tBUT), Schirmer test, corneal staining (CS) score, lid margin telangiectasia (LMT), meibomian gland secretion (MGS), and conjunctival injection (CI). RESULTS: In the short-term treatment, the experimental group showed a statistically significant improvement in the ocular surface disease index (OSDI; P<0.001), tBUT (P=0.004), Schirmer test score (P=0.008) and LMT (P=0.021) by repeated measure ANOVA. Additionally, mean changes from baseline in OSDI (P<0.001), tBUT (P=0.001), Schirmer test score (P=0.029), CS score (P=0.047), LMT (P=0.002), CI (P=0.030) were improved better in the experimental group than in the control group at 3mo. However, there was no significant difference between the two groups in MGS (P=0.67). CONCLUSION: In dry eyes with MGD, 0.05% CsA improves the tear film stability as well as subjective ocular discomfort, and is effective in controlling lid margin inflammation.http://www.ijo.cn/en_publish/2018/4/20180409.pdf6000.05% cyclosporine0.1% hyauronatemeibomian gland dysfunctiondry eye
collection DOAJ
language English
format Article
sources DOAJ
author Ho-Yun Kim
Ji-Eun Lee
Ha-Na Oh
Ju-Whan Song
Sang-Youp Han
Jong-Soo Lee
spellingShingle Ho-Yun Kim
Ji-Eun Lee
Ha-Na Oh
Ju-Whan Song
Sang-Youp Han
Jong-Soo Lee
Clinical efficacy of combined topical 0.05% cyclosporine A and 0.1% sodium hyaluronate in the dry eyes with meibomian gland dysfunction
International Journal of Ophthalmology
600
0.05% cyclosporine
0.1% hyauronate
meibomian gland dysfunction
dry eye
author_facet Ho-Yun Kim
Ji-Eun Lee
Ha-Na Oh
Ju-Whan Song
Sang-Youp Han
Jong-Soo Lee
author_sort Ho-Yun Kim
title Clinical efficacy of combined topical 0.05% cyclosporine A and 0.1% sodium hyaluronate in the dry eyes with meibomian gland dysfunction
title_short Clinical efficacy of combined topical 0.05% cyclosporine A and 0.1% sodium hyaluronate in the dry eyes with meibomian gland dysfunction
title_full Clinical efficacy of combined topical 0.05% cyclosporine A and 0.1% sodium hyaluronate in the dry eyes with meibomian gland dysfunction
title_fullStr Clinical efficacy of combined topical 0.05% cyclosporine A and 0.1% sodium hyaluronate in the dry eyes with meibomian gland dysfunction
title_full_unstemmed Clinical efficacy of combined topical 0.05% cyclosporine A and 0.1% sodium hyaluronate in the dry eyes with meibomian gland dysfunction
title_sort clinical efficacy of combined topical 0.05% cyclosporine a and 0.1% sodium hyaluronate in the dry eyes with meibomian gland dysfunction
publisher Press of International Journal of Ophthalmology (IJO PRESS)
series International Journal of Ophthalmology
issn 2222-3959
2227-4898
publishDate 2018-04-01
description AIM: To investigate the efficacy of combined topical 0.05% cyclosporine A (CsA; Restasis®, Allergan pharmaceuticals, USA) and 0.1% sodium hyaluronate treatment in dry eyes with meibomian gland dysfunction (MGD). METHODS: In a retrospective analysis, 53 patients (106 eyes) with MGD were enrolled and performed lid warm massage for 10min daily and be instilled preservative free sodium hyaluronate 0.1% eye drops 4 times daily. Patients were divided into subjects treated with topical 0.05% CsA and preservative free sodium hyaluronate vehicle (experimental group, n=74 eyes) and subjects treated with the preservative free sodium hyaluronate vehicle (control group, n=32 eyes). They were evaluated at baseline and 1, 2, and 3mo for subjective symptoms and objective signs including tear film break-up time (tBUT), Schirmer test, corneal staining (CS) score, lid margin telangiectasia (LMT), meibomian gland secretion (MGS), and conjunctival injection (CI). RESULTS: In the short-term treatment, the experimental group showed a statistically significant improvement in the ocular surface disease index (OSDI; P<0.001), tBUT (P=0.004), Schirmer test score (P=0.008) and LMT (P=0.021) by repeated measure ANOVA. Additionally, mean changes from baseline in OSDI (P<0.001), tBUT (P=0.001), Schirmer test score (P=0.029), CS score (P=0.047), LMT (P=0.002), CI (P=0.030) were improved better in the experimental group than in the control group at 3mo. However, there was no significant difference between the two groups in MGS (P=0.67). CONCLUSION: In dry eyes with MGD, 0.05% CsA improves the tear film stability as well as subjective ocular discomfort, and is effective in controlling lid margin inflammation.
topic 600
0.05% cyclosporine
0.1% hyauronate
meibomian gland dysfunction
dry eye
url http://www.ijo.cn/en_publish/2018/4/20180409.pdf
work_keys_str_mv AT hoyunkim clinicalefficacyofcombinedtopical005cyclosporineaand01sodiumhyaluronateinthedryeyeswithmeibomianglanddysfunction
AT jieunlee clinicalefficacyofcombinedtopical005cyclosporineaand01sodiumhyaluronateinthedryeyeswithmeibomianglanddysfunction
AT hanaoh clinicalefficacyofcombinedtopical005cyclosporineaand01sodiumhyaluronateinthedryeyeswithmeibomianglanddysfunction
AT juwhansong clinicalefficacyofcombinedtopical005cyclosporineaand01sodiumhyaluronateinthedryeyeswithmeibomianglanddysfunction
AT sangyouphan clinicalefficacyofcombinedtopical005cyclosporineaand01sodiumhyaluronateinthedryeyeswithmeibomianglanddysfunction
AT jongsoolee clinicalefficacyofcombinedtopical005cyclosporineaand01sodiumhyaluronateinthedryeyeswithmeibomianglanddysfunction
_version_ 1725709392682156032